Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study

• Published in: Dermatology and therapy Vol. 11; no. 5; pp. 1613 - 1621
• Main Authors: Nguyen, Hao T., Pham, Nhi T. U., Tran, Tu N. A., Nguyen, Nhuong T. T., Vu, Thao T. P.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01-10-2021; Springer
• Subjects: Dermatology; Drug therapy; Internal Medicine; Medicine; Medicine & Public Health; Oral and Maxillofacial Surgery; Original Research; Patient outcomes; Plastic Surgery; Psoriasis; Quality of Life Research; Vietnam; Secukinumab; Vietnam; Effectiveness; Psoriasis; Real-world
• DOI: 10.1007/s13555-021-00581-1
• EISSN: 2190-9172
• ISSN: 2193-8210

Introduction
Plaque psoriasis (PsO), characterized by demarcated, erythematous, scaly skin, can have a substantial negative impact on patients’ quality of life. This observational (non-interventional) retrospective study was conducted to characterize treatment patterns and response among patients with plaque PsO treated with secukinumab under routine medical practice in Vietnam.
Methods
Patient medical records from the specialized clinic of the Ho Chi Minh City Hospital of Dermato-Venereology (
N
 = 236) were collected. Patients (male or female) aged ≥ 18 years with moderate-to-severe chronic plaque PsO, defined as > 10% involvement of the body surface area (BSA > 10) or a Psoriasis Area and Severity Index (PASI) score > 10 and a Dermatology Life Quality Index (DLQI) score > 10, were included.
Results
In total, 230 patients met the inclusion criteria and were included in the intention-to-treat (ITT) population, the majority of whom were men (66.1%). At baseline, the mean ± standard deviation (SD) age of the ITT population was 41.46 ± 14.29 years, mean disease duration was 7.91 ± 7.91 years, and 27% (
n
 = 62) were obese. More than 90% of the patients were biologic naïve prior to initiation of secukinumab therapy. At week 4, 54.6% patients (
n
 = 124) achieved ≥ 75% reduction in PASI scores from baseline (PASI 75). By week 16, 81.1, 68.9, and 36.5% of the overall population (
n
 = 180, 153, and 81) achieved PASI scores of 75, 90, and 100, respectively; 66.1% of the overall population (
n
 = 154) reported DLQI scores of 0/1 by week 16. The effectiveness of secukinumab was validated in subgroups of patients with or without obesity, concomitant conditions (hepatitis B virus, hepatitis C virus, diabetes, high blood pressure, gout, and/or obesity [body mass index ≥ 30 kg/m
2
]), and concomitant psoriatic arthritis (PsA).
Conclusion
The study validated the real-world effectiveness of secukinumab in Vietnamese patients irrespective of obesity, concomitant conditions, and concomitant PsA status.